CANNAINVESTOR Magazine March / April 2017 - Page 51

Retail Investor's Perspective

The article above ( also references the fact that using Cannabis as an effective medication to combat bacteria based diseases dates back decades. In 1935, for example, cannabis tablets were used to treat gonorrhea.

Perhaps most compelling was an article appearing in the MIT Technology Review titled “Rewriting Life: A New MRSA Defense. Marijuana extracts kill antibiotic-resistant MRSA without a high.” The authors noted:

Given the availability of C. sativa strains producing high concentrations of nonpsychotropic cannabinoids, this plant represents an interesting source of antibacterial agents to address the problem of multidrug resistance in MRSA and other pathogenic bacteria. This issue has enormous clinical implications, since MRSA is spreading throughout the world and, in the United States, currently accounts for more deaths each year than AIDS.

Ground breaking research utilizing cannabis is making the headlines on a regular basis and when the benefits of treatment are observable, measurable, and repeatable we know there is something to it. For example, the work at

Aegis Biotech, a private company, may prove pivotal for the 1 in 165 children diagnosed with an illness with no cure: Pediatric Diffuse Intrinsic Pontine Glioma (DIPG). Aegis Biotech The rescheduling of Cannabis needs to happen for this type of research to continue and expand – the rescheduling will happen. But this sector is not just about designing new drugs and treatments because sometimes everything old is new again: